Darunavir

Research use only, not for human use.

A potent, selective HIV-1 protease inhibitor that is extremely potent against laboratory HIV-1 strains and primary clinical isolates with IC50 of 3 nM, IC90 of 9 nM.

A potent, selective HIV-1 protease inhibitor that is extremely potent against laboratory HIV-1 strains and primary clinical isolates with IC50 of 3 nM, IC90 of 9 nM; blockes the infectivity and replication of HIV-1(NL4-3) variants with IC50 of 3-29 nM, also potent against multi-PI-resistant clinical HIV-1 variants isolated from patients; used to treat and prevent HIV/AIDS.HIV Infection Approved(In Vitro):Darunavir (TMC114, 1a) has a stability comparable to other protease inhibitors.Darunavir (TMC114, UIC-94017) blocks the infectivity and replication of each of HIV-1NL4-3 variants exposed to and selected for resistance to Ro 31-8959, MK-639, AG1341, or ABT 538 at concentrations up to 5 μM (IC50s, 0.003 to 0.029 μM), although it was less active against HIV-1NL4-3 variants selected for resistance to VX-478 (IC50, 0.22 μM).

Darunavir (TMC114, 1a) has a stability comparable to other protease inhibitors.Darunavir (TMC114, UIC-94017) blocks the infectivity and replication of each of HIV-1NL4-3 variants exposed to and selected for resistance to Ro 31-8959, MK-639, AG1341, or ABT 538 at concentrations up to 5 μM (IC50s, 0.003 to 0.029 μM), although it was less active against HIV-1NL4-3 variants selected for resistance to VX-478 (IC50, 0.22 μM).

——

TMC-114 | UIC-94017

Microbiology/Virology

HIV

HIVProtease

Infection

HIV Infection

206361-99-1

547.6636

C27H37N3O7S

>98% (HPLC)

10 mM in DMSO

CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CO[C@@H]3[C@H]2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N

Carbamic acid, N-[(1S,2R)-3-[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester

(-20℃)

With Ice Pack

≥ 2 years